Form 4: Director Boosts Stake in Bicycle Therapeutics

Bicycle Therapeutics director Jose-Carlos Gutierrez-Ramos acquired 9,500 restricted share units and 19,000 stock options.

Summary

• Jose-Carlos Gutierrez-Ramos, a Director at Bicycle Therapeutics PLC, acquired 9,500 Ordinary Shares in the form of Restricted Share Units (RSUs) on January 2, 2026.
• These RSUs will vest in four equal installments on March 15, 2026, June 15, 2026, September 15, 2026, and December 15, 2026.
• Each RSU represents a contingent right to receive one ordinary share, with a reported acquisition price of $0.
• Additionally, Mr. Gutierrez-Ramos acquired 19,000 Stock Options (right to buy) on January 2, 2026, with an exercise price of $7.08.
• These stock options will also vest in four equal installments on March 15, 2026, June 15, 2026, September 15, 2026, and December 15, 2026, and expire on January 2, 2036.
• Following these transactions, Mr. Gutierrez-Ramos beneficially owns 32,500 Ordinary Shares and 19,000 Stock Options.

Sentiment

Score: 7

Explanation: Director's acquisition of equity awards signals confidence in the company's future prospects, which is a positive indicator.

Positives

• The acquisition of restricted share units and stock options by a director signals confidence in the company's future performance and strategic direction.
• Equity awards align the interests of the director with those of shareholders, incentivizing long-term value creation.

Future Outlook

This filing is a transactional report and does not contain forward-looking statements or guidance.

Industry Context

This filing reports an individual insider transaction and does not provide broader industry context or trends.

Comparison to Industry Standards

• NA

Stakeholder Impact

• Shareholders may view the director's increased equity stake as a positive signal of management's commitment and belief in the company's long-term success.

Next Steps

• The vesting of the restricted share units and stock options will occur in four equal installments on March 15, 2026, June 15, 2026, September 15, 2026, and December 15, 2026.

Key Dates

Recommendation

The director's acquisition of restricted share units and stock options indicates management confidence, which is a positive signal for current shareholders. However, this single transaction alone is not sufficient to warrant a 'buy' recommendation without further fundamental analysis.

Keywords

Bicycle Therapeutics, BCYC, Form 4, Insider Transaction, Stock Options, Restricted Share Units, Director, Equity Award